NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 40 resultados LastUpdate Última actualización 29/05/2017 [14:17:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 2 nextPage   Mostrar por página


METHOD FOR PREVENTING OR TREATING OCULAR DISORDERS

NºPublicación: US2017136093A1 18/05/2017

Solicitante:
ZIETCHICK RES INST LLC [US]

Resumen de: US2017136093A1

A method for treating ocular-disorders which, involve angiogenesis or neovascularization as part of their pathologic process. These types of retinal disorders can be categorized as (a) retinal vascular disorders (such as diabetic retinopathy, retinal vein occlusions and retinopathy of prematurity), (b) subretinal neovascular disorders (such as neovascular age-related macular degeneration, ocular histoplasmosis, pathologic myopia) (c) intraocular tumors (such as ocular melanoma, ocular lymphoma and retino-blastoma). The treatment for these ocular disorder involves the administration of an effective amount of human chorionic gonadotropin (hCG) antagonists, luteinizing hormone (LH) antagonists or hCG/LH receptor antagonists, optionally in combination with at least one additional bioactive agent.



traducir


 

METHODS OF TREATING SKIN DISORDERS USING AN ANTI-IL-31RA ANTIBODY

NºPublicación: US2017137525A1 18/05/2017

Solicitante:
ZYMOGENETICS INC [US]

Resumen de: US2017137525A1

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.



traducir


 

THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY

NºPublicación: US2017136043A1 18/05/2017

Solicitante:
UNIV NORTH CAROLINA CHAPEL HILL [US]

Resumen de: US2017136043A1

Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK−/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.



traducir


 

IL-12 IMMUNOTHERAPY FOR CANCER

NºPublicación: US2017136072A1 18/05/2017

Solicitante:
UNIV HEALTH NETWORK [CA]

Resumen de: US2017136072A1

Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.



traducir


 

DIFFERENTIAL CEREBROSPINAL FLUID REACTIVITY TO PFDN5-ALPHA FOR DETECTION OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: US2017138948A1 18/05/2017

Solicitante:
AMRITA VISHWA VIDYAPEETHAM [IN]

Resumen de: US2017138948A1

A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-α from the patient, detecting reactivity of CSF against the PFDN5-α, comparing reactivity profile of CSF against the PFDN5-α at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.



traducir


 

STAT5 INHIBITORS AND USE THEREOF

NºPublicación: US2017137817A1 18/05/2017

Solicitante:
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]
UNIV DE TECH DE COMPIEGNE [FR]
CENTRE NAT DE LA RECH SCIENT (CNRS) [FR]

Resumen de: US2017137817A1

Provided is a composition of matter binding specifically to STAT5, preferably to STAT5B, including a nucleic acid aptamer, and methods of treatment of cancer, and in particular leukaemia via the inhibition of STAT5 protein. The present invention relates more particularly to specific aptamers of STAT5 protein, and the therapeutic or diagnostic use thereof. Also provided is a method for detecting STAT5 in a biological sample, including contacting a nucleic acid aptamer binding specifically to STAT5 with a sample taken beforehand from a subject and determining the quantity of said aptamer bound to said sample.



traducir


 

TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

NºPublicación: US2017137516A1 18/05/2017

Solicitante:
XENCOR INC [US]

Resumen de: US2017137516A1

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug*day/ml or more.



traducir


 

ECHINOMYCIN FORMULATION, METHOD OF MAKING AND METHOD OF USE THEREOF

NºPublicación: WO2017083403A1 18/05/2017

Solicitante:
CHILDREN'S RES INST CHILDREN'S NAT MEDICAL CENTER [US]

Resumen de: WO2017083403A1

A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.



traducir


 

METHODS TO CLASSIFY MULTIPLE MYELOMA

NºPublicación: WO2017083513A1 18/05/2017

Solicitante:
BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS [US]

Resumen de: WO2017083513A1

The present disclosure provides a classification diagnostic, termed TC10, that uses gene expression to assess the primary aberration for individuals with multiple myeloma.



traducir


 

DETERMINATION OF SYNTHETIC LETHAL PARTNERS OF CANCER-SPECIFIC ALTERATIONS AND METHODS OF USE THEREOF

NºPublicación: WO2017083716A2 18/05/2017

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2017083716A2

Analytic methods and systems for determining synthetic lethal (SL) partners of a gene of interest are provided. Identification of one or a set of candidate SL partners associated with a mutation in a gene of interest provides targeted therapies for precision oncology, provides targets for drug screening, enables repurposing of existing drugs, and for theranostic applications. An SL partner for a recurrent mutation in IDH1 is identified, which IDH1 mutation may be present in hematologic malignancies, such as acute myeloid leukemia (AML) cells and in solid tumors.



traducir


 

ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA

NºPublicación: WO2017083592A1 18/05/2017

Solicitante:
CELATOR PHARMACEUTICALS INC [US]
OREGON HEALTH & SCIENCES UNIV [US]

Resumen de: WO2017083592A1

Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.



traducir


 

METHODS FOR DETERMINING RESISTANCE TO ANTICANCER THERAPY AND COMPOSITION USED THEREFOR

NºPublicación: WO2017082655A1 18/05/2017

Solicitante:
SD GENOMICS CO LTD [KR]

Resumen de: WO2017082655A1

The present invention relates to a pharmaceutical composition for the prevention or treatment of malignant tumor comprising an agent for inhibiting the expression of HMGCLL1 IS3, a pharmaceutical composition for the prevention or treatment of malignant tumor showing resistance to tyrosine kinase inhibitor, a method for determining a drug resistance in an individual having malignant tumors using the expression level of HMGCLL1 IS3, a composition and a kit for diagnosing drug resistance used for said method, a method for determining the probability of developing malignant tumor using the expression level of HMGCLL1 IS3, a method for screening a malignant tumor therapeutic agent using the expression level of HMGCLL1 IS3, a method for predicting malignant tumor prognosis using the expression level of HMGCLL1 IS3, a composition and a kit for predicting the prognosis of malignant tumor including an agent capable of measuring the expression level of HMGCLL1 IS3, a method for determining drug resistance in an individual having malignant tumor using SNP, a composition and a kit for diagnosing drug resistance used for said method, a method for determining the probability of developing malignant tumor using SNP, a method for predicting malignant tumor prognosis using SNP, and a composition and a kit for predicting the prognosis of malignant tumor used for said method. The method of the present invention can effectively predict or diagnose drug tolerance of chronic myelogenous leukemia a



traducir


 

Use of compositions modulating chromatin structure for graft versus host disease (GVHD)

NºPublicación: AU2015342895A1 18/05/2017

Solicitante:
DANA-FARBER CANCER INSTITUTE INC
REGENTS OF THE UNIV OF MINNESOTA

Resumen de: AU2015342895A1

In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).



traducir


 

Immunoglobulin variants and uses thereof

NºPublicación: AU2017202590A1 18/05/2017

Solicitante:
GENENTECH INC

Resumen de: AU2017202590A1

Abstract. The invention provides humanized and chimeric anti-CD20 antibodies for treatment of B-Cell associated diseases such as CD20 positive malignancies and autoimmune diseases, in particular dosage regimen. The present invention is directed to CD-20 antibodies with Fc region substitutions S298A or E333A or K334A or K326A or K326W or K322A, wherein these substitutions improve ADCC or CDC activity of the antibody. Certain aspects of the invention are directed to the use of the CD-20 antibody Rituximab@ (Rituxan@) in the treatment of diseases such as rheumatoid arthritis. The present antibodies are used in treating CD 20 positive cancers such as non-Hodgkin's lymphoma, treating autoimmune disease and inducing apoptosis in B-Cells. The invention is also directed to combination therapies with further chemotherapeutic agents such as doxorubicin, cyclophosphamide, prednisolone or CHOP, with further anti-rheumatic agents or with further immunosuppressive agents such as methotrexate. The invention also encompasses methods of producing CD-20 antibodies using vectors and host cells comprising nucleotide sequences encoding the CD-20 antibodies.



traducir


 

TREATMENT OF LEUKEMIA WITH HISTONE DEACETYLASE INHIBITORS

NºPublicación: EP3166603A1 17/05/2017

Solicitante:
ACETYLON PHARMACEUTICALS INC [US]
TAMANG DAVID LEE [US]

Resumen de: WO2016007423A1

Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.



traducir


 

COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1

NºPublicación: EP3168232A1 17/05/2017

Solicitante:
DANA-FARBER CANCER INST INC [US]
FUND SALES [AR]
THE BRIGHAM AND WOMEN'S HOSPITAL INC [US]
CONSEJO NAC DE INVESTIG CIENT\u00CDFICAS Y TECN (CONICET) [AR]

Resumen de: EP3168232A1

The present invention is based, in part, on the discovery that galectin-1 (Gall) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.



traducir


 

TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: HK1220705A1 12/05/2017

Solicitante:
AMGEN RES (MUNICH) GMBH [DE]

Resumen de: CA2742249A1

The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.



traducir


 

METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS RESISTANT TO PROTEASOME INHIBITOR TREATMENTS

NºPublicación: US2017128518A1 11/05/2017

Solicitante:
MAYO FOUNDATION [US]

Resumen de: US2017128518A1

This document provides methods and materials involved in identifying mammals having blood cancer (e.g., myelomas or lymphomas, including WM, MCL, and DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) as well as methods and materials involved in treating mammals having a blood cancer resistant to a proteasome inhibitor such as bortezomib (e.g., VELCADE®). For example, methods and materials for using the expression level of PSMB9/β1i nucleic acid to identify a mammal as having a blood cancer (e.g., myeloma or lymphoma, such as WM, MCL, or DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) are provided.



traducir


 

COMBINATION THERAPY FOR CANCER

NºPublicación: US2017128448A1 11/05/2017

Solicitante:
CELGENE CORP [US]

Resumen de: US2017128448A1

Provided herein are methods of treating, preventing and/or managing lymphomas and leukemias by administering to a patient Compound A (3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an anti-CD20 antibody or ibrutinib, or a pharmaceutically acceptable salt or solvate thereof



traducir


 

METHOD OF REDUCING PRURITUS USING IL-31 MONOCLONAL ANTIBODIES

NºPublicación: US2017129952A1 11/05/2017

Solicitante:
ZYMOGENETICS INC [US]

Resumen de: US2017129952A1

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.



traducir


 

Administration of Angiocidin for the Treatment of Cancer

NºPublicación: US2017128525A1 11/05/2017

Solicitante:
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]

Resumen de: US2017128525A1

Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.



traducir


 

Deep sequencing of peripheral blood plasma DNA is reliable for confirming the diagnosis of myelodysplastic syndrome

NºPublicación: AU2015346487A1 11/05/2017

Solicitante:
NEOGENOMICS LABORATORIES INC

Resumen de: AU2015346487A1

Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.



traducir


 

METHOD AND KIT FOR DETECTION OF DELTANOID-RESISTANT LEUKEMIA CELLS AND ANTIBODY FOR USE THEREIN

NºPublicación: US2017131281A1 11/05/2017

Solicitante:
WROCLAWSKIE CENTRUM BADAN EIT+ SP Z O O [PL]

Resumen de: US2017131281A1

The present invention relates to a method and a kit and antibodies utilized therein, allowing to distinguish between leukemia cells resistant to and leukemia cells susceptible to differentiation induced by deltanoids.



traducir


 

TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED COMPLICATIONS AND AUTOIMMUNE DISEASES

NºPublicación: WO2017079558A1 11/05/2017

Solicitante:
UNIV COLUMBIA [US]

Resumen de: WO2017079558A1

The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1ε) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1ε inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.



traducir


 

PYRIMIDINE DERIVATIVE AND USE THEREOF

Nº publicación: WO2017076355A1 11/05/2017

Solicitante:
HUBEI BIOLOGICAL MEDICINE IND TECH INST CO LTD [CN]
HUMANWELL HEALTHCARE (GROUP) CO LTD [CN]

Resumen de: WO2017076355A1

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.


traducir



 

Página1 de 2 nextPage Mostrar por página

Volver